Oral contraceptives that contain ethinyl estradiol (0.035 mg) and cyproterone acetate (2 mg) inhibit leukocyte transmigration through endothelial cell monolayers - role of MGF

By Hofbauer R.   Frass M.   Gmeiner B.   Salfinger H.   Salzer H.   Kos T.   Wagner O.   Kapiotis S.   Kaye A.D.  

Fertility and Sterility, Vol. 72, Iss. 4, 1999-10 ,pp. : 652-656

Elsevier

Access to resources Recommend Favorite

Effect of ethinyl estradiol–cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome

By Karakurt Feridun   Carlioglu Ayse   Kaygusuz Ikbal   Gumus Ilknur   Uz Burak   Akdeniz Derya  

Archives of Gynecology and Obstetrics, Vol. 289, Iss. 1, 2014-01 ,pp. : 135-140

Springer Publishing Company

Access to resources Recommend Favorite

Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome

By Pesant Marie-Hélène   Baillargeon Jean-Patrice  

Expert Review of Obstretrics and Gynecology, Vol. 1, Iss. 1, 2006-09 ,pp. : 81-92

Informa Healthcare

Access to resources Recommend Favorite

Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

By Villaseca P   Hormaza P   Cárdenas I   Oestreicher E   Arteaga E  

The European Journal of Contraception and Reproductive Health Care, Vol. 9, Iss. 3, 2004-09 ,pp. : 155-165

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome

By Pehlivanov B.   Mitkov M.  

The European Journal of Contraception and Reproductive Health Care, Vol. 12, Iss. 1, 2007-01 ,pp. : 30-35

Informa Healthcare

Access to resources Recommend Favorite